CN101035517A - 具有活性成分位点和时间-可控胃肠释放的片剂 - Google Patents
具有活性成分位点和时间-可控胃肠释放的片剂 Download PDFInfo
- Publication number
- CN101035517A CN101035517A CNA2005800342686A CN200580034268A CN101035517A CN 101035517 A CN101035517 A CN 101035517A CN A2005800342686 A CNA2005800342686 A CN A2005800342686A CN 200580034268 A CN200580034268 A CN 200580034268A CN 101035517 A CN101035517 A CN 101035517A
- Authority
- CN
- China
- Prior art keywords
- tablet
- active component
- yue
- prednisone
- coatings
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
压力[kg] | 迟滞期[h] |
300 | 3 |
340 | 3.5 |
400 | 3.9 |
460 | 4.5 |
580 | 5 |
介质 | 平均迟滞期[h] | 平均药物释放期[h] |
水 | 4.1 | 0.7 |
pH1.2 | 3.6 | 0.8 |
pH4.5 | 3.8 | 0.9 |
pH6.8 | 4.0 | 0.9 |
FaSSIF | 4.2 | 0.8 |
FeSSIF | 4.1 | 0.9 |
压力 | 平均迟滞期1mg片 | 平均迟滞期5mg片 |
150kg | 2.2 | 2.2 |
200kg | 2.4 | 2.7 |
400kg | 3.4 | 3.9 |
600kg | 4.2 | 5.1 |
800kg | 4.8 | 5.6 |
1200kg | 6.0 |
参数 | 泼尼松IR在2am | 泼尼松TR;半-禁食在8pm | 泼尼松TR;进食状态在8pm | ρ* |
Cmax(ng/mL) | 20.9(19.2-22.7) | 20.3(18.6-22.1) | 22.0(20.1-23.9) | 0.54 |
tmax(h) | 2(1.0-4.0) | 6.0(4.5-10.0) | 6.5(4.5-9.0) | <0.0001 |
tlag(h) | 0.0(0.0-0.5) | 3.5(2.0-5.5) | 4.0(3.5-5.0) | <0.0001 |
AUC0-t(h.ng/mL) | 107(98.8-116) | 108(99.1-117) | 121(111-132) | 0.16 |
AUC0-∞(h.ng/mL) | 109(101-118) | 110(102-119) | 123(114-134) | 0.15 |
t1/2(h) | 2.57(2.51-2.63) | 2.41(2.36-2.47) | 2.41(2.36-2.47) | 0.002 |
参数 | 泼尼松IR在2am | 泼尼松TR;半-禁食在8pm | 泼尼松TR;进食状态在8pm | ρ* |
Cmax(ng/mL) | 135(124-147) | 113(104-123) | 132(121-143) | 0.036 |
tmax(h) | 1.0(0.5-3.0) | 5.0(4.0-9.0) | 5.5(4.5-9.0) | <0.0001 |
tlag(h) | 0.0(0.0-0.5) | 3.5(2.0-5.5) | 3.5(3.0-5.0) | <0.0001 |
AUC0-t(h.ng/mL) | 614(571-661) | 561(520-605) | 647(599-698) | 0.081 |
AUC0-∞(h.ng/mL) | 624(582-670) | 573(533-616) | 658(612-707) | 0.0076 |
t1/2(h) | 2.66(2.63-2.70) | 2.66(2.62-2.69) | 2.71(2.68-2.75) | 0.11 |
泼尼松IR在2am | 泼尼松TR;半-禁食在8pm | 泼尼松TR;进食状态在8pm | ||
N | 26 | 26 | 26 | |
Cmax(ng/ml) | 平均值 | 21.1 | 21.4 | 22.2 |
SD | 3.56 | 5.65 | 3.66 | |
中间值 | 20.8 | 21.4 | 22.2 | |
CV | 16.9 | 26.4 | 16.4 | |
tmax(h) | 平均值 | 2.06 | 6.21 | 6.5 |
SD | 0.68 | 1.22 | 1.11 | |
中间值 | 2 | 6 | 6.5 | |
CV | 33.1 | 19.6 | 17.1 | |
AUC0-∞(ng/ml*h) | 平均值 | 111 | 116 | 126 |
SD | 17.5 | 31 | 24.3 | |
中间值 | 106 | 122 | 130 | |
CV(%) | 15.8 | 26.6 | 19.2 |
泼尼松IR在2am | 泼尼松TR;半-禁食在8pm | 泼尼松TR;进食状态在8pm | ||
N | 26 | 26 | 26 | |
Cmax(ng/ml) | 平均值 | 138 | 121 | 135 |
SD | 22.9 | 32.3 | 24.5 | |
中间值 | 140 | 130 | 135 | |
CV | 16.6 | 26.8 | 18.2 | |
tmax(h) | 平均值 | 1.12 | 5.58 | 5.81 |
SD | 0.67 | 1.2 | 1.16 | |
中间值 | 1 | 4 | 5.5 | |
CV | 59.3 | 21.5 | 19.9 | |
AUC0-∞(ng/ml*h) | 平均值 | 638 | 611 | 680 |
SD | 112 | 178 | 142 | |
中间值 | 646 | 677 | 713 | |
CV(%) | 17.7 | 29.2 | 20.9 |
Claims (110)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310037597.2A CN103284971B (zh) | 2004-09-10 | 2005-09-09 | 具有活性成分位点和时间-可控胃肠释放的片剂 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004043863.3 | 2004-09-10 | ||
DE102004043863A DE102004043863A1 (de) | 2004-09-10 | 2004-09-10 | Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum |
US11/216,469 US20060057200A1 (en) | 2004-09-10 | 2005-09-01 | Tablets with site- and time-controlled gastrointestinal release of active ingredient |
US11/216,469 | 2005-09-01 | ||
PCT/EP2005/009726 WO2006027266A1 (en) | 2004-09-10 | 2005-09-09 | Tablets with site time-controlled gastrointestinal release of active ingredient |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310037597.2A Division CN103284971B (zh) | 2004-09-10 | 2005-09-09 | 具有活性成分位点和时间-可控胃肠释放的片剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101035517A true CN101035517A (zh) | 2007-09-12 |
CN101035517B CN101035517B (zh) | 2013-03-13 |
Family
ID=35276479
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800342686A Active CN101035517B (zh) | 2004-09-10 | 2005-09-09 | 具有活性成分位点和时间-可控胃肠释放的片剂 |
CN201310037597.2A Active CN103284971B (zh) | 2004-09-10 | 2005-09-09 | 具有活性成分位点和时间-可控胃肠释放的片剂 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310037597.2A Active CN103284971B (zh) | 2004-09-10 | 2005-09-09 | 具有活性成分位点和时间-可控胃肠释放的片剂 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20060057200A1 (zh) |
EP (1) | EP2386295A3 (zh) |
JP (1) | JP2010047607A (zh) |
KR (1) | KR20110126757A (zh) |
CN (2) | CN101035517B (zh) |
BR (1) | BRPI0515345A (zh) |
DE (1) | DE102004043863A1 (zh) |
HK (2) | HK1110509A1 (zh) |
IL (1) | IL181680A (zh) |
MX (1) | MX2007002898A (zh) |
RU (2) | RU2577164C2 (zh) |
SG (1) | SG155908A1 (zh) |
ZA (1) | ZA200701900B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102218071A (zh) * | 2010-04-06 | 2011-10-19 | 上海安瀚特生物医药技术有限公司 | 一种微粉化地夫可特口服制剂及其制备方法 |
CN103690545A (zh) * | 2013-11-27 | 2014-04-02 | 河南中帅医药科技股份有限公司 | 口服泼尼松择时释放制剂及其制备方法 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2246293C2 (ru) | 1999-06-14 | 2005-02-20 | Космо С.П.А. | Фармацевтические композиции для перорального введения с регулируемым высвобождением активного ингредиента и маскируемым вкусом |
US8895064B2 (en) * | 1999-06-14 | 2014-11-25 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
JP4908200B2 (ja) * | 2003-04-24 | 2012-04-04 | ヤゴテック アーゲー | 着色されたコアを有する錠剤 |
ATE512659T1 (de) * | 2003-04-24 | 2011-07-15 | Jagotec Ag | Tablette mit verzögerter wirkstofffreigabe und bestimmter formgeometrie |
DE102004043863A1 (de) * | 2004-09-10 | 2006-03-16 | Nitec Pharma Ag | Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum |
EP1807058A1 (en) * | 2004-09-10 | 2007-07-18 | Nitec Pharma Ag | Tablets with site time-controlled gastrointestinal release of active ingredient |
ES2401434T3 (es) * | 2004-11-19 | 2013-04-19 | Glaxosmithkline Llc | Método para dispensar de manera individualizada productos de combinación de fármacos de dosis variable para la individualización de terapias |
SG10201503411QA (en) | 2006-08-03 | 2015-06-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid disease |
AU2010207740B2 (en) * | 2009-01-26 | 2016-06-16 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
NZ582836A (en) * | 2009-01-30 | 2011-06-30 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage |
US8945615B2 (en) * | 2009-02-17 | 2015-02-03 | Mylan Pharmaceuticals Inc. | Controlled release budesonide minitablets |
US8945616B2 (en) * | 2009-02-17 | 2015-02-03 | Mylan Pharmaceuticals Inc. | Controlled release budesonide minitablets |
WO2013030726A1 (en) * | 2011-08-26 | 2013-03-07 | Wockhardt Limited | Programmed drug delivery |
US10154964B2 (en) | 2011-09-07 | 2018-12-18 | Cosmo Technologies Limited | Controlled release and taste masking oral pharmaceutical composition |
US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1230576B (it) | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
JP2558396B2 (ja) | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
WO1994008589A1 (en) * | 1992-10-09 | 1994-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of systemic lupus erythematosus with dehydroepiandrosterone |
US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
IT1282576B1 (it) * | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
HRP970493A2 (en) | 1996-09-23 | 1998-08-31 | Wienman E. Phlips | Oral delayed immediate release medical formulation and method for preparing the same |
US5792476A (en) | 1996-12-19 | 1998-08-11 | Abigo Medical Ab | Sustained release glucocorticoid pharmaceutical composition |
US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
ATE267589T1 (de) | 1998-04-03 | 2004-06-15 | Egalet As | Zusammensetzung mit kontrollierter wirkstoff- freisetzung |
GB9905898D0 (en) | 1999-03-15 | 1999-05-05 | Darwin Discovery Ltd | Controlled-dose formulation |
JP2001010950A (ja) * | 1999-06-29 | 2001-01-16 | Taiyo Yakuhin Kogyo Kk | 安定で良好な薬物放出を有する医薬組成物 |
EP1074249A1 (en) | 1999-07-27 | 2001-02-07 | Jagotec Ag | A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period |
DE10012555A1 (de) * | 2000-03-15 | 2001-09-20 | Merck Patent Gmbh | Glucocorticoide in einer Modified Release-Formulierung |
US20020028240A1 (en) * | 2000-04-17 | 2002-03-07 | Toyohiro Sawada | Timed-release compression-coated solid composition for oral administration |
WO2001080824A2 (en) | 2000-04-19 | 2001-11-01 | Eurand America, Inc. | Dual mechanism timed release dosage forms for low dose drugs |
US6620439B1 (en) | 2000-10-03 | 2003-09-16 | Atul M. Mehta | Chrono delivery formulations and method of use thereof |
MXPA03008293A (es) | 2001-03-13 | 2003-12-11 | Penwest Pharmaceuticals Co | Formas de dosis cronoterapeuticas. |
WO2003075919A1 (fr) * | 2002-03-14 | 2003-09-18 | Daiichi Suntory Pharma Co.,Ltd. | Comprime contenant du chlorhydrate de pilsicainide (voie seche) |
ATE512659T1 (de) | 2003-04-24 | 2011-07-15 | Jagotec Ag | Tablette mit verzögerter wirkstofffreigabe und bestimmter formgeometrie |
JP4908200B2 (ja) * | 2003-04-24 | 2012-04-04 | ヤゴテック アーゲー | 着色されたコアを有する錠剤 |
WO2005027843A2 (en) * | 2003-09-19 | 2005-03-31 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms |
EP1807058A1 (en) * | 2004-09-10 | 2007-07-18 | Nitec Pharma Ag | Tablets with site time-controlled gastrointestinal release of active ingredient |
DE102004043863A1 (de) * | 2004-09-10 | 2006-03-16 | Nitec Pharma Ag | Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum |
-
2004
- 2004-09-10 DE DE102004043863A patent/DE102004043863A1/de not_active Ceased
-
2005
- 2005-09-01 US US11/216,469 patent/US20060057200A1/en not_active Abandoned
- 2005-09-09 EP EP11156296A patent/EP2386295A3/en not_active Withdrawn
- 2005-09-09 SG SG200906036-9A patent/SG155908A1/en unknown
- 2005-09-09 RU RU2011119347/15A patent/RU2577164C2/ru active
- 2005-09-09 CN CN2005800342686A patent/CN101035517B/zh active Active
- 2005-09-09 RU RU2007113168/15A patent/RU2435568C2/ru active
- 2005-09-09 MX MX2007002898A patent/MX2007002898A/es active IP Right Grant
- 2005-09-09 BR BRPI0515345-0A patent/BRPI0515345A/pt not_active Application Discontinuation
- 2005-09-09 CN CN201310037597.2A patent/CN103284971B/zh active Active
- 2005-09-09 KR KR1020117024027A patent/KR20110126757A/ko not_active Application Discontinuation
-
2007
- 2007-03-01 IL IL181680A patent/IL181680A/en active IP Right Grant
- 2007-03-05 ZA ZA200701900A patent/ZA200701900B/en unknown
-
2008
- 2008-02-05 HK HK08101360.2A patent/HK1110509A1/xx unknown
-
2009
- 2009-11-27 JP JP2009269373A patent/JP2010047607A/ja not_active Withdrawn
-
2012
- 2012-03-15 US US13/421,135 patent/US20120213910A1/en not_active Abandoned
-
2014
- 2014-03-11 HK HK14102428.2A patent/HK1189346A1/zh unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102218071A (zh) * | 2010-04-06 | 2011-10-19 | 上海安瀚特生物医药技术有限公司 | 一种微粉化地夫可特口服制剂及其制备方法 |
CN103690545A (zh) * | 2013-11-27 | 2014-04-02 | 河南中帅医药科技股份有限公司 | 口服泼尼松择时释放制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2386295A3 (en) | 2012-04-25 |
EP2386295A2 (en) | 2011-11-16 |
JP2010047607A (ja) | 2010-03-04 |
HK1189346A1 (zh) | 2014-06-06 |
RU2011119347A (ru) | 2012-11-20 |
RU2007113168A (ru) | 2008-10-27 |
IL181680A (en) | 2015-04-30 |
KR20110126757A (ko) | 2011-11-23 |
CN101035517B (zh) | 2013-03-13 |
MX2007002898A (es) | 2007-06-15 |
US20060057200A1 (en) | 2006-03-16 |
HK1110509A1 (en) | 2008-07-18 |
RU2435568C2 (ru) | 2011-12-10 |
BRPI0515345A (pt) | 2008-07-22 |
CN103284971A (zh) | 2013-09-11 |
ZA200701900B (en) | 2008-07-30 |
CN103284971B (zh) | 2016-05-11 |
US20120213910A1 (en) | 2012-08-23 |
IL181680A0 (en) | 2007-07-04 |
RU2577164C2 (ru) | 2016-03-10 |
SG155908A1 (en) | 2009-10-29 |
DE102004043863A1 (de) | 2006-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101035517A (zh) | 具有活性成分位点和时间-可控胃肠释放的片剂 | |
CN1211086C (zh) | 雷诺嗪持续释放制剂 | |
CN1278678C (zh) | 具有高生物利用率的非诺贝特药物组合物及其制备方法 | |
EP1931346B1 (en) | Trazodone composition for once a day administration | |
US20050192259A1 (en) | Aldosterone antagonist compositions for release during aldosterone acrophase | |
CN1777412A (zh) | 具有限定内核几何形状的缓释片剂 | |
JP2008303223A (ja) | 脈動用量薬剤経口送達システム | |
JP7057365B2 (ja) | ミドドリンの組成物およびその使用方法 | |
JPH0482825A (ja) | 徐放性錠剤 | |
KR101363563B1 (ko) | 활성성분의 부위 및 시간 제어적 위장관 방출 정제 | |
CA2528191A1 (en) | Novel formulation of pyridoxal 5'-phosphate and method of preparation | |
AU2013229990A1 (en) | Controlled-release solid dosage forms of mesalamine | |
CN1289069C (zh) | 含有5ht1受体激动剂的药物组合物 | |
JP2012516299A (ja) | 有機化合物のガレヌス製剤 | |
TWI344840B (en) | Modafinil modified release pharmaceutical compositions | |
JP2009545546A (ja) | リウマチ性疾患の遅延放出型グルココルチコイド治療 | |
JP2014504633A (ja) | 経口投与用放出制御医薬組成物 | |
WO2019237446A1 (zh) | 一种曲美他嗪缓释片及其制备方法 | |
EP2392318A1 (en) | A pharmaceutical controlled release composition of losartan | |
CN114588124B (zh) | 一种延迟释放的药物组合物 | |
WO2023285977A1 (en) | Pharmaceutical compositions of ozanimod | |
TW202227070A (zh) | Fxr促效劑之固態分散體調配物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1110509 Country of ref document: HK |
|
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Schaeffler Achim Inventor after: Vergnault Guy Inventor after: Grenier Pascal Inventor before: Schaeffler Achim |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: A. SCHAFFLER TO: A. SCHAFFLER VERGNAULT GUY GRENIER PASCAL |
|
ASS | Succession or assignment of patent right |
Owner name: JAGOTEC AG Free format text: FORMER OWNER: NITEC PHARMA AG Effective date: 20110318 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: REINACH, SWITZERLAND TO: MUTTENZ, SWITZERLAND |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110318 Address after: Swiss Ivy Applicant after: Jagotec AG Address before: Swiss Lai Applicant before: Nitec Pharma AG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1110509 Country of ref document: HK |